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Michael J WonderI read with interest the study by Vitry et al. on the thera-
peutic value of new medicines approved for marketing
in Australia in the mid 2000s using two European classi-
fication systems and their finding that “only a minority
of the new medicines in Australia provide added thera-
peutic value compared to existing treatments” [1].
They seem to be confused about the definition of eco-
nomics and differences between ‘new’ and ‘innovation’
and ‘benefit’ and ‘value’.
According to Vitry et al., “from an economic perspec-
tive, pharmaceutical products are considered innovative as
long as they are new and the success of innovation is de-
fined in terms of sales, with the assumption that higher
sales is a measure of the intrinsic worth of the innovation.”
Economics is the science that deals with the production,
distribution, and consumption of goods and services; in
other words, the study of inputs (resources) and outputs
(outcomes) [2]. In the context of health care, economics is
the study of the (health) benefits of a given intervention
(new or old) and its related costs. The definition does not
encompass aspects of novelty, innovation and sales. Their
statement is more befitting of a pharmaceutical industry
perspective.
Furthermore, Vitry et al. note “between 2000 and 2009,
of the 984 new medicines or new indications approved in
France, more than half did not provide anything new.”
This statement is confusing; perhaps they meant to say
“nothing of therapeutic benefit/gain.”
The magnitude of a medicine’s incremental health gain
(i.e. therapeutic benefit) over current treatment com-
bined with the level of unmet clinical need for effective
interventions for patients with the disease/condition
yields an estimate of its therapeutic value. Such determi-
nations are not straightforward when there is an efficacy
gain and a safety loss; such assessments are currently
made on a case-by-case basis using expert value judg-
ment. In diseases/conditions where there are many treat-
ment options, a new medicine might be therapeuticallyCorrespondence: wonderdrug@optusnet.com.au
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stated.superior to some treatments and similar or even inferior
to others. A new medicine might be therapeutically su-
perior to a low dose of a given medicine but clinically in-
ferior to a higher dose of the same medicine. Vitry et al.
are rather vague on what comparisons they think should
be made for a new medicine.
The determination of a new medicine’s therapeutic
benefit and value currently lies in the realm of the HTA
agencies such as the PBAC than in the realm of the regu-
lators such as the TGA. Vitry et al. claim that this is a role
for the TGA; “another limitation of this study is the lack
of gold standard methodology for the evaluation of the
therapeutic value of new medicines. Regulatory agencies
do not currently use standardized processes but mostly
rely on expert judgment.” The current role of the TGA
does not include the determination a new medicine’s
therapeutic value. I am not aware that the TGA is seeking
to usurp the role of the PBAC.
It should come as no surprise that the TGA approves
new medicines deemed by HTA agencies to be of mod-
est or similar therapeutic benefit/value. The TGA acts
like other medicine regulators in this regard. Vitry et al.
seem to imply that the TGA should only register new
medicines that are associated with a clear therapeutic
benefit; they fail to consider the consequences of having
fewer medicines on the market to the degree that only
one medicine might be available in a given pharmaco-
logical/chemical class (e.g. only one statin). The more
important issue is whether payers pay more for new
medicines that do not provide any additional therapeutic
benefit. There is ample local experience to indicate that
this has not occurred.
Vitry et al. state that “stricter regulatory approval criteria
would ensure better safety of the public”. They do not cite
any examples where the safety of the Australian public has
been compromised as a result of supposedly lax approval
criteria by the TGA. The use of stricter criteria will result
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approval criteria would…and simplify the reimburse-
ment process” but they provide no details on what PBS
processes they refer to.
Finally, the authors claim that the public, health care
professionals and policy makers have a belief that all
new medicines bring a “therapeutic innovation and bet-
ter health outcomes” and that the “use of a simple clas-
sification system could provide a useful, simple and
transparent way to better inform the public and health
professionals on the therapeutic value of new medi-
cines.” Their claim that the public, health care profes-
sionals and policy makers think that all new medicines
are associated with therapeutic value is supported by a
reference that reports on a case study for single new
medicine in the UK. They present no solid evidence to
indicate that such beliefs are widespread in Australia.
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